MX2017016347A - Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal. - Google Patents

Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal.

Info

Publication number
MX2017016347A
MX2017016347A MX2017016347A MX2017016347A MX2017016347A MX 2017016347 A MX2017016347 A MX 2017016347A MX 2017016347 A MX2017016347 A MX 2017016347A MX 2017016347 A MX2017016347 A MX 2017016347A MX 2017016347 A MX2017016347 A MX 2017016347A
Authority
MX
Mexico
Prior art keywords
sinus node
cardiac myosin
combination therapy
current inhibitor
myosin activator
Prior art date
Application number
MX2017016347A
Other languages
English (en)
Other versions
MX379899B (es
Inventor
Andrew Donald Scott Robert
Wasserman Scott
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2017016347A publication Critical patent/MX2017016347A/es
Publication of MX379899B publication Critical patent/MX379899B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Se describen en la presente terapias de combinación para el tratamiento de insuficiencia cardíaca mediante el uso del activador de miosina cardíaca, tal como omecamtiv mecarbil, y un inhibidor de corriente If del nodo sinusal. Se describen adicionalmente en la presente composiciones que comprenden un activador de miosina cardíaca y un inhibidor de corriente If del nodo sinusal.
MX2017016347A 2015-06-26 2016-06-24 Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal MX379899B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185306P 2015-06-26 2015-06-26
PCT/US2016/039198 WO2016210240A1 (en) 2015-06-26 2016-06-24 Combination therapy of cardiac myosin activator and sinus node if current inhibitor

Publications (2)

Publication Number Publication Date
MX2017016347A true MX2017016347A (es) 2018-08-15
MX379899B MX379899B (es) 2025-03-11

Family

ID=56409184

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016347A MX379899B (es) 2015-06-26 2016-06-24 Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal

Country Status (6)

Country Link
US (2) US10543215B2 (es)
EP (1) EP3313444B1 (es)
JP (1) JP6858716B2 (es)
AU (1) AU2016282985B2 (es)
MX (1) MX379899B (es)
WO (1) WO2016210240A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0512193B8 (pt) 2004-06-17 2021-05-25 Cytokinetics Inc composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
AU2014240049C1 (en) 2013-03-14 2019-03-07 Amgen Inc. Heterocyclic compounds and their uses
US11040956B2 (en) 2017-06-30 2021-06-22 Amgen Inc. Synthesis of omecamtiv mecarbil
LT3645002T (lt) 2017-06-30 2025-02-10 Amgen Inc. Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais
UY37879A (es) 2017-09-13 2019-03-29 Amgen Inc Compuestos de bisamida que activan el sarcómero y sus usos
HUE052049T2 (hu) 2018-07-09 2021-04-28 Fis Fabbrica Italiana Sintetici Spa Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására
JP2021534138A (ja) 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び結晶形態
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
TW202233189A (zh) 2020-11-12 2022-09-01 美商安進公司 藉由投與奧美卡替莫卡必爾治療心臟衰竭之方法
TW202300479A (zh) 2021-03-10 2023-01-01 美商安進公司 奧美卡替莫卡必爾之合成
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681862B1 (fr) 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
BRPI0512193B8 (pt) * 2004-06-17 2021-05-25 Cytokinetics Inc composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
FR3001151B1 (fr) * 2013-01-21 2016-04-08 Pf Medicament Association d'un bloqueur de courant sodique lent et d'un inhibiteur du courant if sinusal et les compositions pharmarceutiques la contenant
AU2014240049C1 (en) * 2013-03-14 2019-03-07 Amgen Inc. Heterocyclic compounds and their uses

Also Published As

Publication number Publication date
WO2016210240A1 (en) 2016-12-29
JP6858716B2 (ja) 2021-04-14
US10543215B2 (en) 2020-01-28
MX379899B (es) 2025-03-11
US20180140611A1 (en) 2018-05-24
AU2016282985A1 (en) 2017-12-14
EP3313444B1 (en) 2020-10-21
EP3313444A1 (en) 2018-05-02
US20200108076A1 (en) 2020-04-09
JP2018518501A (ja) 2018-07-12
AU2016282985B2 (en) 2021-07-29
CA2988796A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
DOP2022000172A (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd)
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
UY38481A (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
MX379899B (es) Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal
UY36143A (es) Derivados de pirazolo-pirimidina novedosos
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
GT201500348A (es) Compuestos de pirimidinodiona contra estados cardíacos
ECSP17021897A (es) Compuestos y composiciones como inhibidores de quinasa raf
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
CO2019005059A2 (es) Inhibidores de magl
CR20170478A (es) Compuestos novedosos
DOP2016000173A (es) Heteroarilos y usos de estos
CO2019005038A2 (es) Inhibidores de magl
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
MX2016016583A (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
CR20160316A (es) Compuestos derivados de hidroxiformamida y usos del mismo
BR112018000217A2 (pt) sistemas de distribuição de nanopartículas aperfeiçoados
CL2018000742A1 (es) Uso de trientina para el suministro de cobre a un tejido isquémico
MX2016010524A (es) Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico.
MX2017008373A (es) Compuestos, composiciones y metodos.
MX2018003289A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA AUMENTAR LA RECUPERACION DE TRAUMA DE TEJIDO BLANDO.
BR112017012931A2 (pt) métodos para redução de agregação plaquetária e tratamento de doença cardiovascular e outros distúrbios médicos